Biocytogen, a Chinese clinical stage company, completed its series D1 funding raising USD 142m.
The round was led by CMB International, with participation from investor partners PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures, Cowin Capital, and Baifu Capital.
The company intends to use the funds to further secure the implementation of Project Integrum, a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against all notoriously difficult druggable targets. Taking full advantage of Biocytogen’s integrated technology platforms for antibody discovery, Project Integrum will launch pre-clinical efforts into over 1,000 human diseases currently affecting countless lives.
In August, Beijing Biocytogen Biotechnology Co., Ltd. had announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company.
Whether it’s with RenMab-based target knockout mice, customized target humanized mouse models, in vivo pharmacology screening platforms, or even companion dog translational medicine, Biocytogen is determined to find antibodies with clinical translative value.
Led by Chairman and CEO Dr. Yuelei Shen, Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company works jointly with global partners to accelerate new drug discovery and development.